(UroToday.com) Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity, with several drawbacks, including, (ii) low expression in seminoma, embryonal carcinoma, and teratoma and (ii) ~50% sensitivity. Taken together, pre-orchiectomy serum tumor markers are not ideal to diagnose malignant disease. However, there is growing evidence supporting the use of circulating miR-371a-3p as a superior marker for malignant (viable) germ cell tumor management. At the 2020 Society of Urologic Oncology (SUO) virtual meeting, Dr. Rohit Badia and colleagues presented results of their evaluation of the real-world application of serum miR-371a-3p levels in detecting viable germ cell tumors among patients undergoing partial or radical orchiectomy.